BR0006823A - Composição farmacêutica estabilizada, uso de composto de polipeptìdeo cìclico, preparação de injeção e pacote comercial - Google Patents

Composição farmacêutica estabilizada, uso de composto de polipeptìdeo cìclico, preparação de injeção e pacote comercial

Info

Publication number
BR0006823A
BR0006823A BR0006823-3A BR0006823A BR0006823A BR 0006823 A BR0006823 A BR 0006823A BR 0006823 A BR0006823 A BR 0006823A BR 0006823 A BR0006823 A BR 0006823A
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
polypeptide compound
cyclic polypeptide
injection preparation
commercial package
Prior art date
Application number
BR0006823-3A
Other languages
English (en)
Inventor
Seiji Sawai
Akihiro Kasai
Kazumi Otomo
Original Assignee
Fujisawa Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=16210881&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0006823(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fujisawa Pharmaceutical Co filed Critical Fujisawa Pharmaceutical Co
Publication of BR0006823A publication Critical patent/BR0006823A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/08Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"COMPOSIçãO FARMACêUTICA ESTABILIZADA, USO DE COMPOSTO DE POLIPEPTìDEO CìCLICO, PREPARAçãO DE INJEçãO E PACOTE COMERCIAL". Composição farmacêutica estabilizada na forma liofilizada compreendendo um composto de polipeptídeo cíclico representado pela fórmula geral (I) : onde R¹ é um átomo de hidrogênio ou um grupo acila e R² e R³ são, iguais ou diferentes, um átomo de hidrogênio ou um grupo hidroxila, ou um sal do mesmo e um estabilizante.
BR0006823-3A 1999-07-01 2000-06-29 Composição farmacêutica estabilizada, uso de composto de polipeptìdeo cìclico, preparação de injeção e pacote comercial BR0006823A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP18771399 1999-07-01
PCT/JP2000/004381 WO2001002002A1 (en) 1999-07-01 2000-06-29 Stabilized pharmaceutical composition in lyophilized form

Publications (1)

Publication Number Publication Date
BR0006823A true BR0006823A (pt) 2001-06-05

Family

ID=16210881

Family Applications (2)

Application Number Title Priority Date Filing Date
BR0006823-3A BR0006823A (pt) 1999-07-01 2000-06-29 Composição farmacêutica estabilizada, uso de composto de polipeptìdeo cìclico, preparação de injeção e pacote comercial
BRPI0006823A BRPI0006823B8 (pt) 1999-07-01 2000-06-29 composição farmacêutica estabilizada, preparação de injeção, e kit comercial

Family Applications After (1)

Application Number Title Priority Date Filing Date
BRPI0006823A BRPI0006823B8 (pt) 1999-07-01 2000-06-29 composição farmacêutica estabilizada, preparação de injeção, e kit comercial

Country Status (28)

Country Link
US (2) US6774104B1 (pt)
EP (1) EP1107777B1 (pt)
JP (2) JP3381722B2 (pt)
KR (1) KR100454784B1 (pt)
CN (2) CN100352495C (pt)
AR (1) AR024634A1 (pt)
AT (1) ATE280583T1 (pt)
AU (1) AU752265B2 (pt)
BR (2) BR0006823A (pt)
CA (1) CA2341568C (pt)
CZ (1) CZ295720B6 (pt)
DE (1) DE60015279T2 (pt)
ES (1) ES2225161T3 (pt)
HK (2) HK1040057B (pt)
HU (1) HU229089B1 (pt)
ID (1) ID29468A (pt)
IL (2) IL141455A0 (pt)
MX (1) MXPA01000601A (pt)
NO (1) NO330353B1 (pt)
NZ (1) NZ510290A (pt)
OA (1) OA11601A (pt)
PL (1) PL200141B1 (pt)
PT (1) PT1107777E (pt)
RU (1) RU2251411C2 (pt)
TR (1) TR200100609T1 (pt)
TW (1) TWI233805B (pt)
WO (1) WO2001002002A1 (pt)
ZA (1) ZA200101589B (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI233805B (en) * 1999-07-01 2005-06-11 Fujisawa Pharmaceutical Co Stabilized pharmaceutical composition in lyophilized form as antifungal agent
ITMI20021040A1 (it) * 2002-05-16 2003-11-17 Novuspharma Spa Composizioni farmaceutiche iniettabili di un derivato antracenedionico ad attivita' antitumorale
CN1293880C (zh) * 2002-07-31 2007-01-10 千寿制药株式会社 水性液体制剂和光稳定的水性液体制剂
US8877168B1 (en) 2002-07-31 2014-11-04 Senju Pharmaceuticals Co., Ltd. Aqueous liquid preparations and light-stabilized aqueous liquid preparations
US20060074014A1 (en) * 2002-11-18 2006-04-06 Vicuron Pharmaceuticals Inc. Dalbavancin compositions for treatment of bacterial infections
WO2004045637A1 (en) * 2002-11-18 2004-06-03 Vicuron Pharmaceuticals Inc. Dalbavancin compositions for treatment of bacterial infections
US7119061B2 (en) * 2002-11-18 2006-10-10 Vicuron Pharmaceuticals, Inc. Dalbavancin compositions for treatment of bacterial infections
EP1721610B1 (en) 2004-03-04 2009-05-13 Eisai R&D Management Co., Ltd. Composition containing benzamidine derivative and method for stabilizing benzamidine derivative
WO2005111033A2 (en) * 2004-05-19 2005-11-24 Neurosearch A/S Novel azabicyclic aryl derivatives
WO2006053383A1 (en) * 2004-11-22 2006-05-26 Anadis Ltd Bioactive compositions
KR101307999B1 (ko) * 2004-12-01 2013-09-12 니폰 조키 세야쿠 가부시키가이샤 건조물 및 그 제조방법
CA2614592A1 (en) * 2005-07-20 2007-01-25 Kyowa Medex Co., Ltd. Method for stabilization of peptides in a biological sample
CN1962852B (zh) * 2006-11-27 2011-11-09 西北农林科技大学 红景天多糖在制备抗冻剂中的新用途及其产品和制备方法
CN102614492B (zh) * 2011-01-31 2013-12-11 上海天伟生物制药有限公司 一种含有棘白菌素类抗真菌剂米卡芬净的液体药用组合物
CN102614491B (zh) 2011-01-31 2014-04-16 上海天伟生物制药有限公司 一种含有棘白菌素类抗真菌剂米卡芬净的药用组合物及其制备方法和用途
MX368854B (es) * 2012-05-22 2019-10-18 Paion Uk Ltd Composiciones que comprenden benzodiazepinas de acción corta.
US20140274991A1 (en) 2013-03-15 2014-09-18 Cubist Pharmaceuticals, Inc. Ceftolozane pharmaceutical compositions
US9872906B2 (en) 2013-03-15 2018-01-23 Merck Sharp & Dohme Corp. Ceftolozane antibiotic compositions
KR102329764B1 (ko) 2013-03-15 2021-11-23 머크 샤프 앤드 돔 코포레이션 세프톨로잔 항균성 조성물
CN103330932B (zh) * 2013-04-26 2015-12-23 江苏豪森药业股份有限公司 一种米卡芬净或其盐的药物组合物
CN103330933B (zh) * 2013-04-26 2015-08-05 江苏豪森药业股份有限公司 含有米卡芬净或其盐的药物组合物
PL3003298T3 (pl) * 2013-06-05 2024-07-15 The University Of British Columbia Związki antyfibrogenne, sposoby ich zastosowania
EP3043797B1 (en) 2013-09-09 2020-04-08 Merck Sharp & Dohme Corp. Treating infections with ceftolozane/tazobactam in subjects having impaired renal function
US20150094293A1 (en) 2013-09-27 2015-04-02 Calixa Therapeutics, Inc. Solid forms of ceftolozane
KR101611349B1 (ko) 2014-04-14 2016-04-12 신우철 안정성이 개선된 밀크씨슬 엑스의 제형
EP3150621A4 (en) * 2014-05-29 2017-12-27 Shanghai Techwell Biopharmaceutical Co., Ltd Composition of cyclic peptide compound, preparation method for same, and uses thereof
JP6779787B2 (ja) * 2014-12-05 2020-11-04 Meiji Seikaファルマ株式会社 ジアザビシクロオクタン誘導体の結晶及び安定な凍結乾燥製剤の製造法
WO2016107890A1 (en) 2014-12-31 2016-07-07 Galenicum Health S.L. Stable pharmaceutical compositions comprising micafungin
EP3058958B1 (en) 2015-02-23 2018-09-19 Selectchemie AG Anidulafungin composition
WO2018112330A1 (en) 2016-12-16 2018-06-21 Baxter International Inc. Micafungin compositions
US11185527B2 (en) 2017-06-26 2021-11-30 Wayne State University Methods and compositions relating to steroid hormone receptor-dependent cancers
RU2666148C1 (ru) * 2017-10-05 2018-09-06 Общество с ограниченной ответственностью "Новые Антибиотики" Способ получения водорастворимой лиофилизированной формы соли бис(2-тио-4,6-диоксо-1,2,3,4,5,6-гексагидропиримидин-5-ил)-(4-нитрофенил)метана
EP3485873A1 (en) 2017-11-17 2019-05-22 Cadila Healthcare Limited Stable pharmaceutical injectable compositions of micafungin

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03193735A (ja) 1989-12-22 1991-08-23 Shionogi & Co Ltd グリコペプチド系抗生物質の安定化組成物
JPH03240727A (ja) 1990-02-15 1991-10-28 Toyo Jozo Co Ltd ニューモシスチス・カリニ肺炎治療剤
FI912873A (fi) * 1990-06-18 1991-12-19 Fujisawa Pharmaceutical Co Ny polypeptidfoerening och foerfarande foer dess framstaellning.
JP3193735B2 (ja) 1991-07-24 2001-07-30 株式会社リコー カラー画像形成装置の搬送装置
JPH0651641A (ja) 1992-07-30 1994-02-25 Olympus Optical Co Ltd 湿式現像装置
JPH06172204A (ja) * 1992-12-09 1994-06-21 Asahi Chem Ind Co Ltd アクレアシン類含有リポソーム製剤およびその製造法
JP3240727B2 (ja) 1993-02-25 2001-12-25 ソニー株式会社 偏平型陰極線管の画像歪補正装置
IL109615A (en) * 1993-05-17 2000-12-06 Fujisawa Pharmaceutical Co Cyclic polypeptide derivatives processes for the preparation thereof and pharmaceutical compositions containing the same
RU2165423C2 (ru) 1994-10-07 2001-04-20 Фудзисава Фармасьютикал Ко., Лтд. Полипептидное соединение, способ его получения и фармацевтическая композиция
GB9512854D0 (en) * 1995-06-23 1995-08-23 Wellcome Found Novel formulation
CN1161462C (zh) * 1996-03-08 2004-08-11 藤泽药品工业株式会社 环脂肽物的脱酰化方法
AR006598A1 (es) * 1996-04-19 1999-09-08 Merck Sharp & Dohme "composiciones anti-fungosas, su uso en la manufactura de medicamentos y un procedimiento para su preparación"
JPH09301997A (ja) 1996-05-17 1997-11-25 Yamanouchi Pharmaceut Co Ltd 新規環状ペプチド系化合物
AUPO371596A0 (en) * 1996-11-19 1996-12-12 Fujisawa Pharmaceutical Co., Ltd. New compound
FR2755857B1 (fr) * 1996-11-19 1998-12-24 Rhone Poulenc Rorer Sa Compositions pharmaceutiques stabilisees, a base de quinupristine et de dalfopristine et leur preparation
AUPO381496A0 (en) * 1996-11-25 1996-12-19 Fujisawa Pharmaceutical Co., Ltd. New compound
JPH10279498A (ja) * 1997-04-07 1998-10-20 Nippon Shinyaku Co Ltd 慢性関節リウマチ治療剤
JP3544847B2 (ja) * 1998-01-16 2004-07-21 三菱電機株式会社 光学的情報再生方法および装置
EP1156782B1 (en) * 1999-03-03 2005-05-04 Eli Lilly And Company Echinocandin pharmaceutical formulations containing micelle-forming surfactants
JP2002538097A (ja) * 1999-03-03 2002-11-12 イーライ リリー アンド カンパニー 薬学的経口ecb処方物および組成物の作製方法
TWI233805B (en) * 1999-07-01 2005-06-11 Fujisawa Pharmaceutical Co Stabilized pharmaceutical composition in lyophilized form as antifungal agent

Also Published As

Publication number Publication date
AU5572200A (en) 2001-01-22
EP1107777A1 (en) 2001-06-20
DE60015279D1 (de) 2004-12-02
KR100454784B1 (ko) 2004-11-05
CZ295720B6 (cs) 2005-10-12
IL141455A0 (en) 2002-03-10
HK1040057A1 (en) 2002-05-24
HUP0103740A2 (hu) 2002-02-28
CN1636591A (zh) 2005-07-13
US6774104B1 (en) 2004-08-10
EP1107777B1 (en) 2004-10-27
KR20010072903A (ko) 2001-07-31
BRPI0006823B1 (pt) 2020-01-07
CA2341568A1 (en) 2001-01-11
JP2003503462A (ja) 2003-01-28
NZ510290A (en) 2003-07-25
PL346297A1 (en) 2002-01-28
TR200100609T1 (tr) 2001-07-23
US20040157769A1 (en) 2004-08-12
HU229089B1 (en) 2013-07-29
JP2002363097A (ja) 2002-12-18
IL141455A (en) 2006-12-31
WO2001002002A1 (en) 2001-01-11
CN100352495C (zh) 2007-12-05
PT1107777E (pt) 2005-01-31
HK1040057B (zh) 2005-08-05
AU752265B2 (en) 2002-09-12
NO20010893D0 (no) 2001-02-22
NO330353B1 (no) 2011-04-04
BRPI0006823B8 (pt) 2021-05-25
CZ20011186A3 (cs) 2001-09-12
CA2341568C (en) 2011-10-25
TWI233805B (en) 2005-06-11
CN1179748C (zh) 2004-12-15
RU2251411C2 (ru) 2005-05-10
AR024634A1 (es) 2002-10-16
CN1315865A (zh) 2001-10-03
OA11601A (en) 2004-07-30
MXPA01000601A (es) 2002-04-08
PL200141B1 (pl) 2008-12-31
ATE280583T1 (de) 2004-11-15
DE60015279T2 (de) 2005-05-25
ZA200101589B (en) 2002-09-02
JP3381722B2 (ja) 2003-03-04
JP4691866B2 (ja) 2011-06-01
US7112565B2 (en) 2006-09-26
ID29468A (id) 2001-08-30
HK1080724A1 (en) 2006-05-04
HUP0103740A3 (en) 2002-08-28
NO20010893L (no) 2001-04-24
ES2225161T3 (es) 2005-03-16

Similar Documents

Publication Publication Date Title
BR0006823A (pt) Composição farmacêutica estabilizada, uso de composto de polipeptìdeo cìclico, preparação de injeção e pacote comercial
BR0111639A (pt) Uso de uma molécula de ácido oligodeoxinucléico, e composição farmacêutica contendo a mesma
MX9801716A (es) Derivados de meta-guanidina, urea, tiourea o acido aminobenzoico azaciclico, como antagonistas de integrina.
BRPI9908319A (pt) composto amino cíclico, composição farmacêutica, medicamento contendo um composto amino cíclico ou um sal farmacologicamente aceitável do mesmo, e, uso de um composto amino cíclico ou um sal farmacologicamente aceitável do mesmo.
DK0889876T3 (da) Meta-substituerede phenylensulfonamidderivater
BR0213877A (pt) Compostos orgânicos
BR0014133A (pt) Uso de um composto, composto, métodos de preparação de um composto, e para inibir aurora 2 quinase em um animal de sangue quente, e, composição farmacêutica
BR9806413A (pt) Composto e uso do mesmo
KR870700620A (ko) 신규 약리학적 화합물
BR9810021A (pt) Derivados 9-oxima-eritromicina
FR2677984B1 (fr) Derives d'imidazoline n-substitues, leur preparation, les compositions pharmaceutiques en contenant.
BR0108679A (pt) Novos compostos
BR9909781A (pt) Composto de formula (i), processo para sua preparação, composição farmacêutica compreendendo dito composto, seu uso e método.
DE69932424D1 (de) Melanocortin 1 rezeptorselektive verbindungen
NO20021859L (no) Nye oligosakkarider, deres fremstilling samt farmasöytiske preparater inneholdende oligosakkaridene
HUP0001164A2 (hu) PF1022-ciklodepszipeptid-származékok
BR9712140A (pt) Agentes e processos para inibir a produção de citoquina, a adesão de cédulas e a produção de tnf - alfa e uso de um composto.
DE69920362D1 (de) Neue Makrolidderivate
BR9913183A (pt) Composto, uso do mesmo, processo para prepará-lo, processo para tratar um indivìduo humano ou animal, e, composição farmacêutica
TR200000153T2 (tr) İl-5 inhibite eden 6-azaurasil türevleri.
EE200200252A (et) Antikehade kasutamine vaktsiinidena, antikehi sisaldavad farmatseutilised kompositsioonid, meetod antikehapreparaadi valmistamiseks ja meetod farmatseutilise kompositsiooni valmistamiseks
NO983691L (no) Forbindelser tilh°rende amidiniumfamilien, farmas°ytiske preparater inneholdende disse samt anvendelse derav
NO974563D0 (no) Nye taxoider, deres fremstilling samt farmasöytiske preparater inneholdende forbindelsene
WO1999033825A8 (en) N-phenylamide and n-pyridylamide derivatives, method of preparing them and pharmaceutical compositons containing them
DK0447116T3 (da) Urinstof-derivater, deres fremstilling samt lægemidler indeholdende sådanne derivater

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP)

Free format text: TRANSFERIDO POR FUSAO DE: FUJISAWA PHARMACEUTICAL CO., LTD.

B25D Requested change of name of applicant approved

Owner name: ASTELLAS PHARMA INC. (JP)

Free format text: ALTERADO DE: YAMANOUCHI PHARMACEUTICAL CO., LTD.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.20 NA RPI NO 2494 DE 23/10/2018 POR TER SIDO INDEVIDA.

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 07/01/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 29/06/2000 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 29/06/2020